Press Releases July 30, 2026 06:45 AM

Apollo Announces Conversion Rate for Mandatory Convertible Preferred Stock

Apollo Global Management Sets Conversion Rate for Mandatory Convertible Preferred Stock as July 31 Conversion Date Approaches

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
APO

Apollo Global Management announced the conversion rate for its 6.75% Series A Mandatory Convertible Preferred Stock set to convert into common stock on July 31, 2026. Each preferred share will convert into 0.5074 shares of common stock, with cash paid for fractional shares. A final quarterly dividend will be paid on the conversion date.

Apollo Announces Conversion Rate for Mandatory Convertible Preferred Stock
APO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Apollo's 6.75% Series A Mandatory Convertible Preferred Stock will convert into common shares at a rate of 0.5074 on July 31, 2026.
  • Holders will receive a final quarterly dividend of $0.8438 per share on the preferred stock before conversion.
  • Apollo is a global alternative asset manager with over $1 trillion in assets under management as of March 2026, impacting financial services and asset management sectors.

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Apollo Global Management, Inc. (NYSE: APO) (the “Company”) announced today that its outstanding 6.75% Series A Mandatory Convertible Preferred Stock (the “Preferred Stock”) will automatically convert into shares of the Company’s common stock on July 31, 2026 (the “conversion date”). The conversion rate for each share of Preferred Stock will be 0.5074 shares of the Company’s common stock. Cash will be paid in lieu of fractional shares of common stock.

As previously announced, holders of record at the close of business on July 15, 2026 will separately receive a final quarterly cash dividend of $0.8438 per share on the Preferred Stock, payable on the conversion date.

About Apollo

Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, our investing expertise across our fully integrated platform has served the financial return needs of our clients and provided businesses with innovative capital solutions for growth. Through Athene, our retirement services business, we specialize in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Our patient, creative and knowledgeable approach to investing aligns our clients, businesses we invest in, our employees and the communities we impact, to expand opportunity and achieve positive outcomes. As of March 31, 2026, Apollo had approximately $1.03 trillion of assets under management. To learn more, please visit www.apollo.com.

Contacts

Noah Gunn
Global Head of Investor Relations
Apollo Global Management, Inc.
(212) 822-0540
[email protected]

Joanna Rose
Global Head of Corporate Communications
Apollo Global Management, Inc.
(212) 822-0491
[email protected]


Risks

  • Conversion of preferred stock into common shares may dilute existing shareholders' ownership stakes, impacting stock valuation in the financial sector.
  • Market conditions at the time of conversion could affect the common stock price and investor sentiment.
  • Any changes in regulatory or economic environment could influence Apollo's asset management business performance, affecting financial market stability.

More from Press Releases

Stantec joint venture selected by U.S. Army Corps of Engineers to advance coastal resilience on Charleston’s peninsula Jul 30, 2026 Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights Jul 30, 2026 Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing Jul 30, 2026 Mobilicom Secures New Design Win for AI-Enabled Autonomous Weapon Systems Jul 30, 2026 Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109 Jul 30, 2026